Vascular therapies in lung injury

Mahesh Bommaraju, Vasanth H. Kumar, Satyanarayana Lakshminrusimha, Rita M. Ryan, Frederick C. Morin

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

This chapter details vascular-based therapies for lung injury and associated acute respiratory failure. Physiological processes contributing to the disrup- tion of pulmonary vascular regulation in lung injury are also described (Chapter 8 gives additional details on mechanisms and mediators important in pulmonary vascular dysfunction). During acute injury, the overall bal- ance of vasoconstriction and vasodilation in the lungs is shifted towards vasoconstriction, leading to ventilation=perfusion (VA=Q) mismatching, increased pulmonary vascular resistance (PVR), and pulmonary hyperten- sion (PH). These factors, along with associated decreases in cardiac output, compromise gas exchange and reduce systemic oxygen delivery. This chap- ter discusses pharmacologic therapies targeting various aspects of injury- associated pulmonary vascular pathophysiology. Particular coverage is devoted to the clinical use of short-acting inhaled vasodilators normally synthesized by the vascular endothelium: nitric oxide (NO) and prostacyclin (PGI2). Therapies utilizing phosphodiesterase (PDE) inhibitors or other agents that work in concert with NO and PGI2 are also covered. In addition, the use of selective vasoconstrictors, anticoagulants, and growth factors in the treatment of pulmonary vascular dysfunction is also noted. An important emphasis of discussion is that continuing mechanistic basic research is crucial for improving understanding about regulatory pathways and processes involved in vascular pathology in lung injury to facilitate future therapeutic development.

Original languageEnglish (US)
Title of host publicationLung Injury
Subtitle of host publicationMechanisms, Pathophysiology, and Therapy
PublisherCRC Press
Pages705-746
Number of pages42
ISBN (Electronic)9780203025642
ISBN (Print)9780824757939
StatePublished - Jan 1 2005
Externally publishedYes

Fingerprint

Lung Injury
Blood Vessels
Epoprostenol
Lung
Vasoconstriction
Nitric Oxide
Therapeutics
Physiological Phenomena
Phosphodiesterase Inhibitors
Acute Lung Injury
Vascular Endothelium
Vasoconstrictor Agents
Vasodilator Agents
Pulmonary Hypertension
Vasodilation
Respiratory Insufficiency
Cardiac Output
Vascular Resistance
Anticoagulants
Ventilation

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Bommaraju, M., Kumar, V. H., Lakshminrusimha, S., Ryan, R. M., & Morin, F. C. (2005). Vascular therapies in lung injury. In Lung Injury: Mechanisms, Pathophysiology, and Therapy (pp. 705-746). CRC Press.

Vascular therapies in lung injury. / Bommaraju, Mahesh; Kumar, Vasanth H.; Lakshminrusimha, Satyanarayana; Ryan, Rita M.; Morin, Frederick C.

Lung Injury: Mechanisms, Pathophysiology, and Therapy. CRC Press, 2005. p. 705-746.

Research output: Chapter in Book/Report/Conference proceedingChapter

Bommaraju, M, Kumar, VH, Lakshminrusimha, S, Ryan, RM & Morin, FC 2005, Vascular therapies in lung injury. in Lung Injury: Mechanisms, Pathophysiology, and Therapy. CRC Press, pp. 705-746.
Bommaraju M, Kumar VH, Lakshminrusimha S, Ryan RM, Morin FC. Vascular therapies in lung injury. In Lung Injury: Mechanisms, Pathophysiology, and Therapy. CRC Press. 2005. p. 705-746
Bommaraju, Mahesh ; Kumar, Vasanth H. ; Lakshminrusimha, Satyanarayana ; Ryan, Rita M. ; Morin, Frederick C. / Vascular therapies in lung injury. Lung Injury: Mechanisms, Pathophysiology, and Therapy. CRC Press, 2005. pp. 705-746
@inbook{38af6d212269499cbf58f174a3cc4d0d,
title = "Vascular therapies in lung injury",
abstract = "This chapter details vascular-based therapies for lung injury and associated acute respiratory failure. Physiological processes contributing to the disrup- tion of pulmonary vascular regulation in lung injury are also described (Chapter 8 gives additional details on mechanisms and mediators important in pulmonary vascular dysfunction). During acute injury, the overall bal- ance of vasoconstriction and vasodilation in the lungs is shifted towards vasoconstriction, leading to ventilation=perfusion (VA=Q) mismatching, increased pulmonary vascular resistance (PVR), and pulmonary hyperten- sion (PH). These factors, along with associated decreases in cardiac output, compromise gas exchange and reduce systemic oxygen delivery. This chap- ter discusses pharmacologic therapies targeting various aspects of injury- associated pulmonary vascular pathophysiology. Particular coverage is devoted to the clinical use of short-acting inhaled vasodilators normally synthesized by the vascular endothelium: nitric oxide (NO) and prostacyclin (PGI2). Therapies utilizing phosphodiesterase (PDE) inhibitors or other agents that work in concert with NO and PGI2 are also covered. In addition, the use of selective vasoconstrictors, anticoagulants, and growth factors in the treatment of pulmonary vascular dysfunction is also noted. An important emphasis of discussion is that continuing mechanistic basic research is crucial for improving understanding about regulatory pathways and processes involved in vascular pathology in lung injury to facilitate future therapeutic development.",
author = "Mahesh Bommaraju and Kumar, {Vasanth H.} and Satyanarayana Lakshminrusimha and Ryan, {Rita M.} and Morin, {Frederick C.}",
year = "2005",
month = "1",
day = "1",
language = "English (US)",
isbn = "9780824757939",
pages = "705--746",
booktitle = "Lung Injury",
publisher = "CRC Press",

}

TY - CHAP

T1 - Vascular therapies in lung injury

AU - Bommaraju, Mahesh

AU - Kumar, Vasanth H.

AU - Lakshminrusimha, Satyanarayana

AU - Ryan, Rita M.

AU - Morin, Frederick C.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - This chapter details vascular-based therapies for lung injury and associated acute respiratory failure. Physiological processes contributing to the disrup- tion of pulmonary vascular regulation in lung injury are also described (Chapter 8 gives additional details on mechanisms and mediators important in pulmonary vascular dysfunction). During acute injury, the overall bal- ance of vasoconstriction and vasodilation in the lungs is shifted towards vasoconstriction, leading to ventilation=perfusion (VA=Q) mismatching, increased pulmonary vascular resistance (PVR), and pulmonary hyperten- sion (PH). These factors, along with associated decreases in cardiac output, compromise gas exchange and reduce systemic oxygen delivery. This chap- ter discusses pharmacologic therapies targeting various aspects of injury- associated pulmonary vascular pathophysiology. Particular coverage is devoted to the clinical use of short-acting inhaled vasodilators normally synthesized by the vascular endothelium: nitric oxide (NO) and prostacyclin (PGI2). Therapies utilizing phosphodiesterase (PDE) inhibitors or other agents that work in concert with NO and PGI2 are also covered. In addition, the use of selective vasoconstrictors, anticoagulants, and growth factors in the treatment of pulmonary vascular dysfunction is also noted. An important emphasis of discussion is that continuing mechanistic basic research is crucial for improving understanding about regulatory pathways and processes involved in vascular pathology in lung injury to facilitate future therapeutic development.

AB - This chapter details vascular-based therapies for lung injury and associated acute respiratory failure. Physiological processes contributing to the disrup- tion of pulmonary vascular regulation in lung injury are also described (Chapter 8 gives additional details on mechanisms and mediators important in pulmonary vascular dysfunction). During acute injury, the overall bal- ance of vasoconstriction and vasodilation in the lungs is shifted towards vasoconstriction, leading to ventilation=perfusion (VA=Q) mismatching, increased pulmonary vascular resistance (PVR), and pulmonary hyperten- sion (PH). These factors, along with associated decreases in cardiac output, compromise gas exchange and reduce systemic oxygen delivery. This chap- ter discusses pharmacologic therapies targeting various aspects of injury- associated pulmonary vascular pathophysiology. Particular coverage is devoted to the clinical use of short-acting inhaled vasodilators normally synthesized by the vascular endothelium: nitric oxide (NO) and prostacyclin (PGI2). Therapies utilizing phosphodiesterase (PDE) inhibitors or other agents that work in concert with NO and PGI2 are also covered. In addition, the use of selective vasoconstrictors, anticoagulants, and growth factors in the treatment of pulmonary vascular dysfunction is also noted. An important emphasis of discussion is that continuing mechanistic basic research is crucial for improving understanding about regulatory pathways and processes involved in vascular pathology in lung injury to facilitate future therapeutic development.

UR - http://www.scopus.com/inward/record.url?scp=85056544274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056544274&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:85056544274

SN - 9780824757939

SP - 705

EP - 746

BT - Lung Injury

PB - CRC Press

ER -